Passiatore M, Perna A, De-Vitis R, Taccardo G
Department of Orthopaedics and Traumatology, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
Department of Orthopaedics and Traumatology, Universita Cattolica del Sacro Cuore, Rome, Italy.
Malays Orthop J. 2020 Mar;14(1):1-6. doi: 10.5704/MOJ.2003.001.
Carpal tunnel syndrome is one of the most common peripheral neuropathies. Only a few studies evaluate the efficacy of "nutraceuticals" on peripheral nerves and neuropathic pain. The aim of the present investigation is to evaluate the role of Alfa-Lipoic Acid-R (ALA-R) on clinical and functional outcomes in patients affected by mild to moderate carpal tunnel syndrome.
The present investigation is a prospective randomised controlled open label study, performed at our Hand Surgery Department (Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome) from October 2018 to March 2019. The enrolled patients were divided in two groups: Group A (ALA-R 600mg once day for 60 days) and Group B (control Group, no drug administration).
134 patients (74 F, 60 M) met the inclusion and exclusion criteria. In Group A, there was a statistically significant pain reduction compared to the control Group. Using the Boston Carpal Tunnel Questionnaire, there were no significant improvements in the other symptoms and function.
ALA-R full dose administration for two months leads to positive short term results in terms of symptoms and function improvement, even if the surgical carpal tunnel release remains the treatment of choice.
腕管综合征是最常见的周围神经病变之一。仅有少数研究评估了“营养保健品”对周围神经和神经性疼痛的疗效。本研究的目的是评估R-硫辛酸（ALA-R）对轻至中度腕管综合征患者临床和功能结局的作用。
本研究是一项前瞻性随机对照开放标签研究，于2018年10月至2019年3月在我们的手外科（罗马圣心天主教大学综合医院基金会IRCCS）进行。纳入的患者分为两组：A组（每天一次服用600mg ALA-R，共60天）和B组（对照组，不给予药物）。
134例患者（74例女性，60例男性）符合纳入和排除标准。与对照组相比，A组疼痛减轻具有统计学意义。使用波士顿腕管问卷，其他症状和功能无显著改善。
即使手术松解腕管仍是首选治疗方法，但ALA-R全剂量给药两个月在症状和功能改善方面可带来积极的短期效果。
